Cargando…
Donor Screening Revisions of Fecal Microbiota Transplantation in Patients with Ulcerative Colitis
Fecal microbiota transplantation (FMT) has been recognized as a promising treatment for dysbiosis-related diseases. Since 2014, FMT has been utilized to treat ulcerative colitis (UC) in our clinical studies and has shown efficacy and safety. As donor screening (DS) is the primary step to ensure the...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8879222/ https://www.ncbi.nlm.nih.gov/pubmed/35207328 http://dx.doi.org/10.3390/jcm11041055 |
_version_ | 1784658847436111872 |
---|---|
author | Zhang, Xiaochen Ishikawa, Dai Nomura, Kei Fukuda, Naoyuki Haraikawa, Mayuko Haga, Keiichi Shibuya, Tomoyoshi Mita, Toshihiro Nagahara, Akihito |
author_facet | Zhang, Xiaochen Ishikawa, Dai Nomura, Kei Fukuda, Naoyuki Haraikawa, Mayuko Haga, Keiichi Shibuya, Tomoyoshi Mita, Toshihiro Nagahara, Akihito |
author_sort | Zhang, Xiaochen |
collection | PubMed |
description | Fecal microbiota transplantation (FMT) has been recognized as a promising treatment for dysbiosis-related diseases. Since 2014, FMT has been utilized to treat ulcerative colitis (UC) in our clinical studies and has shown efficacy and safety. As donor screening (DS) is the primary step to ensure the safety of FMT, we report our experience with DS and present the screening results to improve the prospective DS criteria and provide references for future studies. The donor candidates were screened according to the DS criteria. The first DS criteria were proposed in June 2014 and revised substantially in May 2018. We further sorted the screening results and costs of laboratory tests. From June 2014 to April 2018, the DS eligibility rate was 50%. The total laboratory testing cost for each candidate was JPY 17,580/USD 160.21. From May 2018 to September 2021, the DS eligibility rate was 25.6%. The total laboratory testing cost for each candidate was JPY 40,740/USD 371.36. The reduction in donor eligibility rates due to more stringent criteria should be considered for cost and safety. Studies must consider the latest updates and make timely modifications in the DS criteria to ensure patient safety. |
format | Online Article Text |
id | pubmed-8879222 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88792222022-02-26 Donor Screening Revisions of Fecal Microbiota Transplantation in Patients with Ulcerative Colitis Zhang, Xiaochen Ishikawa, Dai Nomura, Kei Fukuda, Naoyuki Haraikawa, Mayuko Haga, Keiichi Shibuya, Tomoyoshi Mita, Toshihiro Nagahara, Akihito J Clin Med Article Fecal microbiota transplantation (FMT) has been recognized as a promising treatment for dysbiosis-related diseases. Since 2014, FMT has been utilized to treat ulcerative colitis (UC) in our clinical studies and has shown efficacy and safety. As donor screening (DS) is the primary step to ensure the safety of FMT, we report our experience with DS and present the screening results to improve the prospective DS criteria and provide references for future studies. The donor candidates were screened according to the DS criteria. The first DS criteria were proposed in June 2014 and revised substantially in May 2018. We further sorted the screening results and costs of laboratory tests. From June 2014 to April 2018, the DS eligibility rate was 50%. The total laboratory testing cost for each candidate was JPY 17,580/USD 160.21. From May 2018 to September 2021, the DS eligibility rate was 25.6%. The total laboratory testing cost for each candidate was JPY 40,740/USD 371.36. The reduction in donor eligibility rates due to more stringent criteria should be considered for cost and safety. Studies must consider the latest updates and make timely modifications in the DS criteria to ensure patient safety. MDPI 2022-02-17 /pmc/articles/PMC8879222/ /pubmed/35207328 http://dx.doi.org/10.3390/jcm11041055 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Zhang, Xiaochen Ishikawa, Dai Nomura, Kei Fukuda, Naoyuki Haraikawa, Mayuko Haga, Keiichi Shibuya, Tomoyoshi Mita, Toshihiro Nagahara, Akihito Donor Screening Revisions of Fecal Microbiota Transplantation in Patients with Ulcerative Colitis |
title | Donor Screening Revisions of Fecal Microbiota Transplantation in Patients with Ulcerative Colitis |
title_full | Donor Screening Revisions of Fecal Microbiota Transplantation in Patients with Ulcerative Colitis |
title_fullStr | Donor Screening Revisions of Fecal Microbiota Transplantation in Patients with Ulcerative Colitis |
title_full_unstemmed | Donor Screening Revisions of Fecal Microbiota Transplantation in Patients with Ulcerative Colitis |
title_short | Donor Screening Revisions of Fecal Microbiota Transplantation in Patients with Ulcerative Colitis |
title_sort | donor screening revisions of fecal microbiota transplantation in patients with ulcerative colitis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8879222/ https://www.ncbi.nlm.nih.gov/pubmed/35207328 http://dx.doi.org/10.3390/jcm11041055 |
work_keys_str_mv | AT zhangxiaochen donorscreeningrevisionsoffecalmicrobiotatransplantationinpatientswithulcerativecolitis AT ishikawadai donorscreeningrevisionsoffecalmicrobiotatransplantationinpatientswithulcerativecolitis AT nomurakei donorscreeningrevisionsoffecalmicrobiotatransplantationinpatientswithulcerativecolitis AT fukudanaoyuki donorscreeningrevisionsoffecalmicrobiotatransplantationinpatientswithulcerativecolitis AT haraikawamayuko donorscreeningrevisionsoffecalmicrobiotatransplantationinpatientswithulcerativecolitis AT hagakeiichi donorscreeningrevisionsoffecalmicrobiotatransplantationinpatientswithulcerativecolitis AT shibuyatomoyoshi donorscreeningrevisionsoffecalmicrobiotatransplantationinpatientswithulcerativecolitis AT mitatoshihiro donorscreeningrevisionsoffecalmicrobiotatransplantationinpatientswithulcerativecolitis AT nagaharaakihito donorscreeningrevisionsoffecalmicrobiotatransplantationinpatientswithulcerativecolitis |